LRRK2-IN-17 (Compound 6) is an orally active LRRK2 inhibitor ( IC 50 : 3.5 and 3.3 nM for WT and G2019S, respectively). LRRK2-IN-17 inhibits RET kinase ( IC 50 : 59 nM). LRRK2-IN-17 can be used in cancer and Parkinson's disease (PD) research.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Signaling Pathways > LRRK2 | Products > Signaling Pathways > RET
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.